Back to Top Skip to main content

Health agencies investigating severe lung illnesses linked to e-cigarette use

"While the CDC investigation of the possible cases of lung illness and deaths reportedly associated with the use of e-cigarette products is ongoing, Service members and their families or dependents are encouraged not to use e-cigarette products,” advised Dr. Terry Adirim, Deputy Assistant Secretary of Defense, Health Services Policy and Oversight. (DoD photo) "While the CDC investigation of the possible cases of lung illness and deaths reportedly associated with the use of e-cigarette products is ongoing, Service members and their families or dependents are encouraged not to use e-cigarette products,” advised Dr. Terry Adirim, Deputy Assistant Secretary of Defense, Health Services Policy and Oversight. (DoD photo)

Recommended Content:

Tobacco-Free Living | Substance Abuse | Public Health

The Centers for Disease Control and Prevention is working with the Food and Drug Administration, state and local health departments, and other public health partners to investigate a multistate outbreak of severe lung illnesses linked to e-cigarette use.

As of Sept. 6, the CDC said, 33 states as well as the U.S. Virgin Islands have reported more than 450 possible cases of lung illnesses associated with using e-cigarette products. Six deaths have been confirmed in California, Illinois, Indiana, Kansas, Minnesota, and Oregon.

The products under investigation include devices, liquids, refill pods, and cartridges. A cause has not yet been identified, the CDC says, but all reported cases have a history of using e-cigarette products.

The CDC said the investigation so far has not identified a specific substance or e-cigarette product that is linked to all cases. Many patients report using e-cigarette products with liquids that contain cannabinoid products such as tetrahydrocannabinol, or THC.

The CDC recommends that people consider not using e-cigarette products while the investigation is ongoing. Those who do use these products should seek prompt medical care if they experience symptoms including coughing, shortness of breath, or chest pain; nausea, vomiting, or diarrhea; or fatigue, fever, or weight loss.

Some patients reported that their symptoms developed anywhere from over a few days to over several weeks, the CDC said.

Regardless of the investigation, the CDC warns that pregnant women, youth, and young adults should not use e-cigarette products. Adults who do use these products should not buy them off the street, nor modify them with substances not intended by the manufacturer.

"While the CDC investigation of the possible cases of lung illness and deaths reportedly associated with the use of e-cigarette products is ongoing, Service members and their families or dependents are encouraged not to use e-cigarette products,” advised Dr. Terry Adirim, Deputy Assistant Secretary of Defense, Health Services Policy and Oversight. “Current users of e-cigarettes are encouraged to report any symptoms like those reported in this outbreak including cough, shortness of breath, chest pain nausea, vomiting, diarrhea fatigue, fever, or weight loss and seek medical care promptly."

E-cigarette use sometimes is called vaping. As the CDC explains, the products are also known as e-cigs, vapes, e-hookahs, vape pens, and ENDS (electronic nicotine delivery systems).

E-cigarettes come in different shapes and sizes. Some may look like regular cigarettes, cigars, or pipes. Others look like everyday items such as pens and flash drives.

Most have a battery heating element, and a place to hold a liquid. E-cigarettes produce an aerosol by heating a liquid that usually contains nicotine – the addictive drug in regular cigarettes, cigars, and other tobacco products – flavorings, and other chemicals. Users inhale this aerosol into their lungs. Bystanders can also breathe in this aerosol when the user exhales into the air.

The Military Health System offers information on the health risks of tobacco use as well as resources for how to stop using it or avoid starting.

You also may be interested in...

DHA PI 6025.15: Management of Problematic Substance Use by DoD Personnel

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (aa), establishes the Defense Health Agency’s (DHA) procedures to assign responsibilities for problematic alcohol and drug use identification, diagnosis, and treatment for DoD military personnel.

  • Identification #: 6025.15
  • Date: 4/16/2019
  • Type: DHA Procedural Instruction
  • Topics: Substance Abuse

DHA PI 6490.02: Behavioral Health (BH) Treatment and Outcomes Monitoring

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (k): a. Establishes the Defense Health Agency’s (DHA) procedures for the collection and analysis of BH outcome data. b. Addresses how DoD will standardize BH outcome data collection to: assess variations in mental health and substance use care among in-garrison medical treatment facilities (MTFs) and clinics; assess the relationship of treatment protocols and practices to BH outcomes; and identify barriers to provider implementation of evidence-based clinical guidance approved by DoD. c. Designates the Army as the DoD lead Service for maintenance and sustainment of the Behavioral Health Data Portal (BHDP) in specialty care mental health and substance use clinics, referred to collectively as BH clinics, until BHDP functionality can be integrated with GENESIS or another electronic health record (EHR) system managed by DHA. d. Designates DHA Information Operations (J-6) as lead on transitioning BHDP functional requirements related to outcomes monitoring to future EHR data collection platforms and processes.

DHA PI 6025.04: Pain Management and Opioid Safety in the MHS

Policy

The purpose of our MHS Pain Management Campaign is to enable Clinical Communities to provide evidence-based pain management guided by clinical practice guidelines (CPGs): effectively treat acute and chronic pain; promote non-pharmacologic treatment; prevent acute pain from becoming chronic; and minimize use of opioids with appropriate prescribing only when indicated. The Pain Management Clinical Support Service achieves these ends through clinical improvements in pain care, clinician and patient education, and research. This Defense Health Agency-Procedural Instruction (DHA-PI) is a dual effort between the Pain Management Clinical Support Service and the Clinical Communities to achieve our stated purpose through implementation of the MHS Stepped Care Model.

Embedded Fragment Analyses

Policy

Clarification of the Requirement for Continuation of Semi-Annual Reporting of Results of Embedded Fragment Analyses

Influenza Surveillance Program

Policy

Sentinel Sites for the 2014-2015 Influenza Surveillance Program

DoD Instruction 1010.04: Problematic Substance Use by DoD Personnel

Policy

Establishes policies, assigns responsibilities, and prescribes procedures for problematic alcohol and drug use prevention, identification, diagnosis, and treatment for DoD military and civilian personnel.

  • Identification #: DoD Instruction 1010.04
  • Date: 2/20/2014
  • Type: Instructions
  • Topics: Substance Abuse

Deployment Limiting Mental Disorders and Psychotrophic Medications

Policy

Policy memorandum about Deployment Limiting Mental Disorders and Psychotrophic Medications

Access to Medical Services Who were Exposed to Rabies in Combat Theater

Policy

U.S. Navy/U.S. Marine Corps COSC Policy Update

Policy

Mental Health Assessments for Members of the Armed Forces Deployed in Connection with a Contingency Operation

Policy

Clinical Policy for the Administration of the Anthrax Vaccine Adsorbed

Policy

DoD Directive 6490.5 on Combat Stress Control Programs

Policy
Showing results 1 - 12 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.